Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) Assets Average (2021 - 2025)

Historic Assets Average for SAB Biotherapeutics (SABSW) over the last 5 years, with Q3 2025 value amounting to $106.8 million.

  • SAB Biotherapeutics' Assets Average rose 8461.38% to $106.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.8 million, marking a year-over-year increase of 8461.38%. This contributed to the annual value of $64.1 million for FY2024, which is 497.56% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Assets Average of $106.8 million as of Q3 2025, which was up 8461.38% from $34.1 million recorded in Q2 2025.
  • SAB Biotherapeutics' Assets Average's 5-year high stood at $117.2 million during Q2 2021, with a 5-year trough of $31.9 million in Q3 2023.
  • Its 5-year average for Assets Average is $67.0 million, with a median of $57.8 million in 2024.
  • In the last 5 years, SAB Biotherapeutics' Assets Average crashed by 5217.7% in 2022 and then surged by 8461.38% in 2025.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Assets Average stood at $99.0 million in 2021, then tumbled by 47.79% to $51.7 million in 2022, then rose by 8.57% to $56.1 million in 2023, then dropped by 12.72% to $49.0 million in 2024, then soared by 117.95% to $106.8 million in 2025.
  • Its Assets Average stands at $106.8 million for Q3 2025, versus $34.1 million for Q2 2025 and $41.2 million for Q1 2025.